Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test
- The next-generation pancreatic cancer test by Immunovia achieved a specificity of 98% and a sensitivity of 75% in detecting early-stage pancreatic cancer.
- The test outperformed CA19-9, the commonly used biomarker, making it significantly more accurate.
- The new test includes high-performing protein biomarkers, reducing reliance on CA19-9 and providing definitive positive or negative results for all patients.
- The results confirm the technical advancement of the next-generation test over Immunovia's first-generation test, IMMray PanCan-d.
- The new test overcomes the limitations of the first-generation test, allowing for testing in patients who do not produce CA19-9, including those of African ancestry.
- None.
Insights
Immunovia's advancement from IMMray PanCan-d to its next-generation pancreatic cancer detection test holds substantial promise, particularly given the reported specificity of
From an investor's perspective, this innovation might translate into an increased addressable market and potential revenue growth. Moreover, the absence of indeterminate results could bolster the test's clinical utility and adoption rate. As Immunovia moves closer to potential commercialization, it’s important for investors to consider the regulatory pathways and insurance reimbursements, which serve as critical factors for market penetration and ultimately impact the stock's performance.
The next-generation test's ability to detect early-stage PDAC with such precision is a laudable milestone in oncological care. Sensitivity and specificity are cornerstone parameters in the effectiveness of any diagnostic tool. With a
Equipping clinicians with this test could reshape the diagnostic landscape for pancreatic cancer, traditionally fraught with late detection. As understanding deepens about the economic burden of late-stage cancer care versus early intervention, the value proposition of such a test can extend beyond patient outcomes and influence healthcare cost dynamics. This potential paradigm shift could be a pivotal consideration for investors gauging the long-term trajectory of Immunovia's stock.
Immunovia's announcement is indicative of a strategic move that could disrupt the current standard of care for pancreatic cancer and create a significant market opportunity. Beyond the biomedical implications, the financials of the diagnostics market are driven by product adoption, competitive advantage and the reimbursement environment.
Investors should monitor the company's pipeline progress, engagement with the FDA for approval and strategies for health insurance coverage. These factors will influence the time-to-market and the financial impact. Typically, a product that addresses unmet medical needs and shows superiority over existing options, like the traditional CA19-9, tends to be well-positioned for market adoption, which could positively influence the company's valuation. While early in its commercialization journey, this product could be a catalyst for future earnings inflections, particularly if adoption rates and pricing strategies align with market expectations.
In the study, Immunovia's next-generation test demonstrated specificity of 98 percent and sensitivity of 75 percent in detecting early stage (1 and 2) pancreatic ductal adenocarcinoma (PDAC), a very aggressive and the most common form of pancreatic cancer. The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.
Importantly, these results confirm the technical advancement of the next-generation test over Immunovia's first-generation test, IMMray PanCan-d. The next-generation test includes high-performing protein biomarkers, making the test less reliant on CA19-9. This is a major achievement as around 10 percent of patients, including many patients of African ancestry, do not produce CA19-9, so the IMMray PanCan-d test could not be used in those patients. The results with the new test were achieved including PDAC patients with low CA19-9 values.
Furthermore, the new test does not provide indeterminate or "borderline" results; all patients are classified as positive or negative for pancreatic cancer. With the first-generation Immunovia test, IMMray PanCan-d, about 10 percent of patients received a test result of "borderline", creating indecision for clinicians.
The next-generation test is now established on a broadly used ELISA platform, resulting in more precise protein measurement, faster testing, and lower cost of goods sold.
"Pancreatic cancer is a brutal and lethal cancer. People at risk for pancreatic cancer need a simple, fast, and easy blood test to detect cancer early. We are very excited about the potential of our test to meet this need and increase survival rates for these patients," says Jeff Borcherding, CEO and President of Immunovia.
The model development study was designed to select the highest performing biomarkers to include in the next-generation test, to define the algorithm to produce a diagnostic result, and to provide an initial assessment of the test's clinical performance. The study included 481 blood samples from the
Immunovia will now move to a second phase of the model development study, expected to be completed in 6 - 8 weeks, in which it will conduct additional statistical analyses to refine and assess the robustness of the test model. In addition, test performance will be evaluated in a more selective cohort of patients at high risk for pancreatic cancer.
In the second and third quarters of 2024, Immunovia will perform several analytical validation steps to verify the accuracy and reproducibility of the protein biomarker measurements. In the fourth quarter of 2024, the company will conduct a large clinical validation study to confirm the performance of the next-generation test, setting the stage for a
Immunovia estimates that there are at least 600,000 individuals in the
For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
+46 709 11 56 08
The information in this report is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 am CET on April 22, 2024.
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/immunovia-announces-positive-results-from-the-model-development-study-for-its-next-generation-pancreatic-cancer-detection-test-302123062.html
SOURCE Immunovia AB
FAQ
What are the key results of Immunovia's model-development study for its next-generation pancreatic cancer test?
How does the new test by Immunovia compare to CA19-9 in detecting pancreatic cancer?
What is the significance of the high-performing protein biomarkers included in Immunovia's next-generation pancreatic cancer test?
How does the new test overcome limitations of Immunovia's first-generation test, IMMray PanCan-d?
